The preliminary safety analysis of the ARCHES trial appears consistent with the safety profile of XTANDI in previous clinical trials in castration-resistant prostate cancer (CRPC). Detailed results will
The SOLO-3 late-stage trial, which evaluated the efficacy and safety of Lynparza, featured 266 patients whose ovarian cancer relapsed following two or more lines of treatment. Patients were
Under the collaboration, Gilead has exclusive options to license worldwide rights to product candidates that emerge from three Scholar Rock TGFβ programs: inhibitors that target activation of latent
According to Pfizer, the combination of the consumer healthcare businesses had registered global sales of nearly $12.7bn in 2017. GSK said that the combination will comprise two portfolios
Under the terms of the agreement, Innovare will use DelSiTech’s technology on its peptide membrane fusion inhibitor, targeting the envelope protein of human immunodeficiency virus-1 (HIV-1). DelSiTech is
The trial was held in patients who previously experienced inadequate responses to two to four classes of preventive treatments. In the study of 838 patients, including those who
The partnership between C4XD and the Horizon Discovery intends to assess synthetic lethal oncology targets identified by the latter’s CRISPR-Cas9 technology. C4XD will apply its 4D shape-based chemistry
The partners will combine the Morphomer platform technology of the Switzerland-based AC Immune with the clinical development expertise and commercial capabilities of Lilly in central nervous system disorders
Under the terms of the agreement, X-Chem will utilize its industry-leading DNA-encoded library (DEX) screening platform and proprietary informatics tools to search for novel hits for Almirall targets.
Targeting this biochemical pathway may help develop new therapies for alleviating the symptoms of anxiety disorders. The lab of Prof. Mike Fainzilber in the Institute’s Biomolecular Sciences Department
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.